Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M208381200 on November 25, 2002

J. Biol. Chem., Vol. 278, Issue 8, 5630-5638, February 21, 2003
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
278/8/5630    most recent
M208381200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hill, D. M.
Right arrow Articles by Kozlowski, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hill, D. M.
Right arrow Articles by Kozlowski, S.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

A Dominant Negative Mutant beta 2-Microglobulin Blocks the Extracellular Folding of a Major Histocompatibility Complex Class I Heavy Chain*

Dawn M. HillDagger , Tina KasliwalDagger , Elie Schwarz, Andrea M. Hebert, Trina Chen, Elena Gubina, Lei Zhang, and Steven Kozlowski§

From the Division of Monoclonal Antibodies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892

The major histocompatibility complex class I (MHC1) molecule plays a crucial role in cytotoxic lymphocyte function. beta 2-Microglobulin (beta 2m) has been demonstrated to be both a structural component of the MHC1 complex and a chaperone-like molecule for MHC1 folding. beta 2m binding to an isolated alpha 3 domain of MHC1 heavy chain at micromolar concentrations has been shown to accurately model the biochemistry and thermodynamics of beta 2m-driven MHC1 folding. These results suggested a model in which the chaperone-like role of beta 2m is dependent on initial binding to the alpha 3 domain interface of MHC1 with beta 2m. Such a model predicts that a mutant beta 2m molecule with an intact MHC1 alpha 3 domain interaction but a defective MHC1 alpha 1alpha 2 domain interaction would block beta 2m-driven folding of MHC1. In this study we generated such a beta 2m mutant and demonstrated that it blocks MHC1 folding by normal beta 2m at the expected micromolar concentrations. Our data support an initial interaction of beta 2m with the MHC1 alpha 3 domain in MHC1 folding. In addition, the dominant negative mutant beta 2m can block T-cell functional responses to antigenic peptide and MHC1.

* This work was supported by the Howard Hughes Medical Institute and Montgomery County Public Schools student intern program.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Contributed equally to this work.

§ To whom correspondence should be addressed: DMA, CBER, FDA, 29 Lincoln Dr., Bldg. 29B-3NN08, HFM-561, Bethesda, MD 20892. Tel.: 301-827-0719; Fax: 301-827-0852; E-mail: kozlowski@cber.fda.gov.

Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Mol Cancer ResHome page
Md. I. Hassan, A. Waheed, S. Yadav, T. P. Singh, and F. Ahmad
Zinc {alpha}2-Glycoprotein: A Multidisciplinary Protein
Mol. Cancer Res., June 1, 2008; 6(6): 892 - 906.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A.-M. Tsimberidou, H. M. Kantarjian, S. Wen, S. O'Brien, J. Cortes, W. G. Wierda, C. Koller, S. Pierce, M. Brandt, E. J. Freireich, et al.
The Prognostic Significance of Serum {beta}2 Microglobulin Levels in Acute Myeloid Leukemia and Prognostic Scores Predicting Survival: Analysis of 1,180 Patients
Clin. Cancer Res., February 1, 2008; 14(3): 721 - 730.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C.-C. Chang, T. Ogino, D. W. Mullins, J. L. Oliver, G. V. Yamshchikov, N. Bandoh, C. L. Slingluff Jr., and S. Ferrone
Defective Human Leukocyte Antigen Class I-associated Antigen Presentation Caused by a Novel beta2-Microglobulin Loss-of-function in Melanoma Cells
J. Biol. Chem., July 7, 2006; 281(27): 18763 - 18773.
[Abstract] [Full Text] [PDF]

Home page
 BioinformaticsHome page
E. Duprat, M.-P. Lefranc, and O. Gascuel
A simple method to predict protein-binding from aligned sequences--application to MHC superfamily and {beta}2-microglobulin
Bioinformatics, February 15, 2006; 22(4): 453 - 459.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
I. A. York, E. P. Grant, A. M. Dahl, and K. L. Rock
A Mutant Cell with a Novel Defect in MHC Class I Quality Control
J. Immunol., June 1, 2005; 174(11): 6839 - 6846.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. J. H. Borysik, S. E. Radford, and A. E. Ashcroft
Co-populated Conformational Ensembles of {beta}2-Microglobulin Uncovered Quantitatively by Electrospray Ionization Mass Spectrometry
J. Biol. Chem., June 25, 2004; 279(26): 27069 - 27077.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2003 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement